A Shock to Lilly's System?
Xigris, the drugmaker's new sepsis treatment, was supposed to help cover sales of Prozac lost to generics. It's falling far short
By David Shook
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.